In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Global Blood Therapeutics (NASDAQ: GBT), with a price target of $83. The company’s shares opened today at $46.05.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.5% and a 56.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $84.56 average price target, representing an 83.6% upside. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $26.10. Currently, Global Blood Therapeutics has an average volume of 1.3M.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
